ReviewFrontiers in medicine2022
Cutaneous vasculitis and vasculopathy in the era of COVID-19 pandemic.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines among Patients with Immune-Mediated Dermatological Diseases: A Systematic Review and Meta-analysis.Acta dermato-venereologica · 2024Pooled it
- Cutaneous Pediatric Vasculitis: A Clinico-Histopathological Overview of Common and Novel Entities.Dermatopathology (Basel, Switzerland) · 2026Review
- COVID-19-associated cutaneous vasculitis with exfoliative erythroderma and extensive scarring: Long-term clinical and laser management.JAAD case reports · 2026Article
- Incidence and clinical features of ANCA-associated vasculitis before and during the COVID-19 pandemic: experience from a single-center in Northern Spain.Frontiers in medicine · 2026Article
- Cutaneous small vessel vasculitis in the COVID-19 era: a systematic review.Skin health and disease · 2025Review
- Onset of leukocytoclastic vasculitis following covid-19 vaccination: case based comprehensive review.Rheumatology international · 2024Review
- Long COVID in Children, Adults, and Vulnerable Populations: A Comprehensive Overview for an Integrated Approach.Diseases (Basel, Switzerland) · 2024Review
- Normocomplementemic Urticarial Vasculitis Following Influenza Vaccination: A Case Report and Review of the Literature.International medical case reports journal · 2024Article
- COVID-19 vaccine-associated vasculitis: A systematic review.SAGE open medicine · 2024Review
- Factors influencing the outcomes of dermatoses during the COVID-19 outbreak in China: a retrospective study.Frontiers in medicine · 2024Article
- Review
- Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future?Life (Basel, Switzerland) · 2023Review
- Cutaneous vasculitis after COVID-19 vaccination in a 41-year-old male.Clinical case reports · 2023Article
- Article
- Cutaneous Adverse Events After COVID-19 Vaccination.Clinical, cosmetic and investigational dermatology · 2023Article
- Association of the Monocyte-to-High-Density Lipoprotein Cholesterol Ratio with Gastrointestinal Involvement of Immunoglobulin a Vasculitis.Clinical, cosmetic and investigational dermatology · 2023Article
- Self-DNA driven inflammation in COVID-19 and after mRNA-based vaccination: lessons for non-COVID-19 pathologies.Frontiers in immunology · 2023Article
- Learning from the Experiences in the COVID-19 Pandemic - Impact on Quality of Life and Challenges for the Staff of a Dermatological Hospital and Rehabilitation Center in Germany: A Retrospective Analysis.Clinical, cosmetic and investigational dermatology · 2023Article
- Herpes Zoster and COVID-19 Vaccination: A Narrative Review.Clinical, cosmetic and investigational dermatology · 2023Review
- Treatment of cutaneous vasculitis.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous vasculitides encompass a heterogeneous group of clinicopathological entities, which may occur as single-organ vasculitis of the skin or present as skin-limited variant of systemic vasculitis (i.e., skin-limited ANCA-associated vasculitis), and are triggered by various factors, including infections, drugs and vaccines. The COVID-19 pandemic has challenged us with a variety of both disease- and vaccine-associated skin manifestations, including vasculitis. Among the latter, cutaneous small-vessel vasculitis, previously known as leukocytoclastic vasculitis, seems to be the most reported in either scenario, i.e., natural infection and vaccination. Vasculopathy without true vasculitic changes on histology develops in but a minority of cases, mostly severe/critical COVID-19 patients, and appears to be the result of endothelial injury due to pauci-immune thromboembolic mechanisms. Herein, we provide an overview of the available literature on COVID-19-associated and anti-SARS-CoV-2-vaccine-associated cutaneous vasculitis. Although evidence is mostly limited to isolated reports, with a proportion of cases lacking histopathological confirmation, ample overlap with pre-pandemic forms is shown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.